Searchable abstracts of presentations at key conferences in endocrinology

ea0020me6 | (1) | ECE2009

Growth in childhood and adolescence as function of hormonal activity and nutrition

Zadik Zvi

A prerequisite milieu for normal growth is an intact hormonal system, adequate nutrition and normal physical activity. Any arm of this triangle, if interrupted, may change the normal growth pattern. Timing and interval range of disruption of this homeostasis, may affect the outcome up to irreversible results. The 3 polynomial growth model of Karlberg helps to detect, past irreversible growth retardation and in foresee and prevent growth deteriorationA no...

ea0041gp139 | Paediatric Endocrinology & Development | ECE2016

2nd year efficacy results of once-weekly administration of CTP-modified human growth hormone (MOD-4023): a phase 2 study in children with growth hormone deficiency

Zelinska Nataliya , Skorodok Julia , Malievsky Oleg , Rosenfeld Ron G , Zadik Zvi , Koren Ronit , Amitzi Leanne , Hershkovitz Oren , Hart Gili , Radziuk Klaudziya

Objective: Growth hormone (GH) replacement therapy currently requires daily injections. This may cause poor compliance, inconvenience and distress for patients. CTP-modified hGH (MOD-4023) has been developed for once-weekly administration in growth hormone deficient (GHD) adults and children. The 18 and 24 month efficacy of once-weekly subcutaneous (SC) administration of MOD-4023 was evaluated in a Phase 2 study in children with GH deficiency.Design and ...

ea0041ep845 | Paediatric endocrinology | ECE2016

Safety and tolerability of once-weekly administration of CTP-modified human growth hormone (MOD-4023): phase 2 study in children with growth hormone deficiency

Zelinska Nataliya , Iotova Violeta , Skorodok Julia , Malievsky Oleg , Rosenfeld Ron G. , Zadik Zvi , Koren Ronit , Amitzi Leanne , Hershkovitz Oren , Hart Gili , Radziuk Klaudziya

Objective: Growth hormone (GH) replacement therapy currently requires daily injections. This may cause poor compliance, inconvenience and distress for patients. CTP-modified human GH (MOD-4023) has been developed for once-weekly administration in growth hormone-deficient (GHD) adults and children. In the present Phase 2 study, the safety and tolerability of once-weekly subcutaneous (SC) administration of MOD-4023 were evaluated in GHD children.Design and...